Fezagepras (sodium)
CAS No. : 1254472-97-3
(Synonyms: Setogepram (sodium); PBI-4050 (sodium))
| Size | Price | Stock |
|---|---|---|
| 5mg | $105 | In-stock |
| 10mg | $170 | In-stock |
| 25mg | $320 | In-stock |
| 50mg | $470 | In-stock |
| 100mg | $685 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-100775 |
| M.Wt: | 228.26 |
| Formula: | C13H17NaO2 |
| Purity: | >98 % |
| Solubility: | H2O : ≥ 100 mg/mL;DMSO : ≥ 64 mg/mL |
Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras sodium decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].
IC50 & Target: GPR40, GPR84[1]
In Vitro: Fezagepras sodium (500 µM; 24 hours) inhibits TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation[2].
Fezagepras sodium (250 or 500 µM; 24 hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis[2].
In Vivo: Fezagepras sodium (100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improvea glucose tolerance in type 2 diabetes eNOS-/-db/db mice[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Fezagepras (sodium)
- Cat. No.:
- HY-100775
- Quantity:
Your information is safe with us.